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TNF/cachectin is made up of 17-kD polypeptides and has diverse biological
effects (reviewed in references 1-3) . The gene encoding TNF is located on
chromosome 6 in tandem with the gene coding for lymphotoxin (LT)' (4, 5) .
Although TNF has been considered to be a product of cells in the mono-
cyte/macrophage lineage, evidence has accumulated that TNF is produced by
other cells. In mouse, a TNF-resistant clone was shown to produce TNF consti-
tutively (6) . In man, NK cell-enriched populations when incubated with NK
target cell lines secretedan inhibitor for colony formation (7) . This inhibitor had
characteristics resembling TNF. With anti-TNF antibodies as a blocking agent
for cytotoxicity assays on L cells, purified NK cells, mitogen-stimulated cytotoxic
T cell clones, and a subclone of HUT-102 were shown to secrete TNF-like
cytotoxins (8-10) . In addition, a T-T hybridoma was induced to secrete TNF
(11) . In a recent study of lymphocyte populations isolated from peripheral blood
and extensively depleted of monocytes, Cuturi et al . (12) provided convincing
evidence thatT lymphocytes were shown to respond to mitogens to secreteTNF.
Anti-CD3 mAbs and tumor promotor PMA have been used to activate Jurkat
cells to secrete IL-2 (13). This combination induces restingT cells to proliferate
in the absence of monocytes (14) . In these systems, the activation of the phos-
phoinositol pathway by anti-CD3 mAbs via the CD3/Ti complex and the activa-
tion of protein kinase C by PMA are required. In the present study, the
stimulation of TNF mRNA accumulation in leukemic T cell lines and the
potentiation of this stimulation by an anti-CD3 mAb in selected lines were
examined . Although there were differences in the amounts of TNF mRNA
accumulated, all T cell lines were shown to synthesize TNF mRNA in response
to these stimuli . The accumulation of LT mRNA under identical experimental
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conditions was compared. Similar approaches were extended to isolated periph-
eral blood T cells. In both cases, it was shown that both anti-CD3 mAb and PMA
were required for the maximal induction of mRNA accumulation for TNF and
LT. These stimuli were capable ofinducing TNF secretion by T leukemia cells
and freshly isolated peripheral blood T cells.
Materials and Methods
Cell Lines.
￿
All cells were maintained in RPMI 1640 (Gibco, Grand Island, NY) with
10% FCS (HyClone Laboratories, Sterile Systems Inc., Logan, UT), 2 mM glutamine, 50
U/ml penicillin, and 50 ag/ml streptomycin, except L-929 cells (from American Type
Culture Collection, Rockville, MD) which were maintained in DMEM (Gibco) with 10%
FCS.
The T cell line KE-4 was derived in our laboratory from a patient with T cell lymphoma.
All other cell lines were generous gifts of Dr. Jun Minowada (Fujisaki Cell Center,
Hayashibara Biochem. Labs. Inc., Fujisaki, Okayama, Japan). The T cell lines CEM,
Jurkat, Molt-4, HSB-2, MT-1, KE-4, and SKW-3 were cured of mycoplasma by several
cycles of BM-Cycline (Boehringer Mannheim Biochemicals, Indianapolis, IN) treatment
and subsequently cloned in soft agar (15) and characterized by Dr. Wei Chen of our
laboratory. Fast-growing clones, free from mycoplasma contamination, were used in this
study. The surface markers of these T cell lines are as follows. (a) CEM: CD2-, CD3+,
CD4+, CD8+; (b) Jurkat: CD2+, CD3+, CD4-, CD8-; (c) Molt-4: CD2-, CD3+, CD4-,
CD8-; (d) HSB-2: CD2-, CD3-, CD4-, CD8-; (e) MT-1 : CD2-, CD3-, CD4+, CD8-; (f)
KE-4: CD2+, CD3-, CD4-, CD8+; (g) SKW-3 : CD2+, CD3-, CD4+, CD8+.
Isolation ofPeripheral Blood T Cells.
￿
Peripheral blood T cells were prepared from buffy
coat preparations obtained from the Oklahoma Blood Institute (Oklahoma City, OK).
After Ficoll-Paque (Pharmacia Fine Chemicals, Piscataway, NJ) centrifugation, the mono-
nuclear cells were fractionated by counterflow centrifugal elutriation in an elutriator
rotor (model JE-6; Beckman Instruments Inc., Palo Alto, CA) as described (16). The
lymphocyte fractions with <0.1 % monocyte contamination as shown by nonspecific
esterase staining (17) were pooled and further depleted of non-T cells by E-rosette
sedimentation (18) followed by nylon wool columns (19). The final T cell preparations
were 98-99% CD2+, and contained <1% CD20+ and <1% surface Ig+ cells as shown by
flow cytometry analysis. Less than 0.01% nonspecific esterase-staining monocytes were
detected in these preparations.
Monoclonal Antibodies.
￿
Anti-CD3 mAb (T3-II, IgGl) was used (14) for activation of
leukemic T cell lines and peripheral blood T cells. mAbs C16 and E43 were made against
isolated human TNF (Wang, C. Y., manuscript in preparation). mAb C16 was used in
Western blot analysis. It reacted with the isolated 17-kD TNF. mAb E43 was chosen for
its ability to block TNF activity as assayed on L cells. Neither of the anti-TNF antibodies
reacted with LT.
cDNA and Oligonucleotide Probes. The mouse TNF cDNA probe in pUC8 was a
generous gift of Dr. B. Beutler at the Howard Hughes Medical Institute at Dallas, TX
(20). This mouse probe was used to isolate a human genomic TNF clone from an EMBL-
3 library (Clontech, Palo Alto, CA). A 3.4-kb Pst I fragment ofthe TNF gene comprising
exons 1-3 and part of exon 4 was used to confirm the Northern blot results obtained
using the TNF oligonucleotide probe. The chicken ,B actin cDNA probe originated from
Dr. M. Kirschner at the University of California at San Francisco, CA (21) and were
subcloned into pT3/T7-19 (Bethesda Research Laboratories, Bethesda, MD). The human
T cell receptor ,B chain cDNA clone Jursl of Yoshikai et al. (22) was obtained from Dr.
L. Pickering (T-Cell Sciences, Cambridge, MA). The IL-2-R cDNA clone (pIL-2R2) was
donated by Drs. Warner Greene (Howard Hughes Medical Institute, Durham, NC) and
Warren Leonard (National Institutes of Health, Bethesda, MD) (23). The IL-2 probe of
Clark et al. (24) was obtained from Drs. S. Clark (Genetics Institute, Cambridge, MA) and
A. Granelli-Piperno (The Rockefeller University, New York, NY). The oligonucleotide
24mer probes 5'-TACAGGCTTGTCACTCGGGGTTCG for human TNF (TNF-I; ref-SUNG ET AL.
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erence 25), and 5'-CATCTTGGGGTGCTGACGGGCAGT for human lymphotoxin
(LT-I; reference 26), and the 30mer 5'-GTGCAATGGTGTGAATCGCAGAGT-
GAAGTG for the putative human X-linked chronic granulomatous disease gene (379
probe; reference 27) encoding the # chain of cytochrome b_Y45 were synthesized by
phosphoramidite chemistry and purified by C-18 reverse-phase HPLC by Syntek (Umea,
Sweden). The CD2 24mer probe 5'-TGTCCTGACCCAAGGCACCCCAGG (28), the
second TNF 25mer probe (TNF-II) 5'-AGGAAGGAGAAGAGGCTGAGGAACA, and
the second LT 24mer oligonucleotide probe (LT-II) 5'-GTGGGGACCAGGAGA-
GAATTGTTG were synthesized and purified by the same methods by Dr. Kenneth
Jackson at the Molecular Biology Resource Facility at the St. Francis Medical Research
Institute in Oklahoma City, OK. The CGD 379 probe detected a 5-kb major band in
Northern blot analysis of myelomonocytic cell lines as described (27). The CD2 oligonu-
cleotide probe detected the two RNA bands at 1.7 and 1.3 kb in T cell lines (28).
Homology search oftheoligonucleotide 24mer probes TNF-Iand LT-I in Genbankusing
default values of the Ifind program of Bionet revealed no homologous sequence with a
ranking <12 and thus no known crosshybridizing human mRNA species. Similar results
were obtained for homology searches for the TNF-II and LT-II oligonucleotide probes.
Methods for plasmid preparation and labeling by nick translation were performed as
described (29), as were the kinasing of oligonucleotide probes by [y-32p]-ATP (New
England Nuclear, Boston, MA).
RNA Preparation and Analysis.
￿
RNA from cell pellets was prepared by ultracentrifu-
gation of the guanidinium thiocyanate cell lysate on a CsCl cushion as described (29).
Poly(A)+-RNA were isolated by oligo(dT)-cellulose columns (29). For Northern blot
hybridizations, RNA was fractionated in 1.4% agarose gels containing 2.2 M formalde-
hyde, as described (29). Transfer of RNA to Genescreen Plus (New England Nuclear)
hybridization, washing, and stripping of probes from blots for re-use followed the rec-
ommendations ofthe supplier. Hybridization of,6 actin, Tcell receptor ,B chain, IL-2, and
IL-2-R probes to the RNA blots were performedat 42°C in 50% formamide, 1% SDS, 1
M NaCI, 10 mM EDTA, 10% dextran sulfate (Pharmacia Fine Chemicals), 50 mM sodium
phosphate, pH 7.0, and 100 Ag/ml sheared and heat-denatured salmon sperm DNA
(Sigma Chemical Co., St. Louis, MO). Mouse TNF cDNA and all oligonucleotide probes
were hybridized to theblots at 41 °C in thesame solution containing only 35% formamide.
Afterovernight hybridization, theblots were washed in three changes of 2X SSCat room
temperature (5 min each), followed by two 30-min washes at 60°C in 2X SSC and 1%
SDS. The blots hybridized with actin, T,B, IL-2, and IL-2-R probes were washed for an
additional 30 min at 60°C in 0.2X SSC and 1% SDS. Blots were exposed to X-Omat
XAR-5, XK-1 (Kodak), or Cronex-4 (DuPont Co., Wilmington, DE) X-ray films.
Western Blotting. Supernatant concentrates were subjected to electrophoresis with
Rainbow prestained molecular weight markers (Amersham Corp., Arlington Heights, IL)
in 12 .5% SDS-polyacrylamide gels under reducing conditions and electrophoretically
transferred to genescreen plus nylon membranes (New England Nuclear) as described
(30). Blocking of nonspecific binding was performed with Carnation nonfat dry milk at
50°C overnight. Reactionsof blots with primary and secondaryantibody were performed
as described (31). The goat anti-mouse IgG secondary antibody wasaffinity purified and
labeled with '25I using iodogen as described by the supplier (Pierce Chemical Co.,
Rockford, IL).
Cytotoxicity Assay.
￿
TNF cytotoxic activity was performed essentially as described (32)
usingactinomycin D-treated L-929 cells as target. Serial dilutions in duplicates of T cell
supernatants or supernatant concentrates were incubated with L-929 cells for 16-20 h
followed by the addition of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT; Sigma Chemical Co.) for 4 h. The cells were then washed once with PBS, the
MTT formazan was solubilized with acidified isopropanol, andthe absorbance at 570 nm
was read with a microELISA autoreader (model MR580; Dynatech Corp., Alexandria,
VA). For anti-TNF blocking experiments, E43 was incubated with serially diluted super-
natant solutions for 4-18 h before addition to the L cells. Thenumber of cytotoxic units
is definedas thereciprocal ofthesupernatant dilution causing50% decrease in absorbance.940 ANTI-CD3 ANTIBODY AND TUMOR NECROSIS FACTOR PRODUCTION
Results
Specificities ofTNFandLT Oligonucleotide Probes.
￿
Two oligonucleotide (24mer
and 25mer) probes forTNF(TNF-I andTNF-II)and two 24meroligonucleotide
probes for LT (LT-I and LT-II) were made for the purpose of Northern analysis
ofTNF andLT mRNAs accumulated in unstimulated or PMA-treated leukemic
T cell lines . Fig . 1 shows the specificities ofTNF-I and LT-I . In this experiment,
a myeloid leukemia cell line ML-1 and a leukemic T cell line HSB-2 were treated
with 30 ng/ml ofPMA for 4 h. The poly(A)+-mRNA was isolated from control
and PMA-treated cultures . Northern blot analysis was carried out under high
stringency hybridization and washing conditions . A mouse TNF cDNA probe
which crosshybridized with human TNF cDNA was also used . Poly(A)'-mRNA
from unstimulated ML-I failed to hybridize with any of the probes . With PMA
treatment, mRNAs that hybridized with both mouse TNF cDNA and TNF-I
probes were synthesized . Both probes identified the same 1.7-kb major and 2 .9-
kb minor bands . This is in agreement with the results of Northern analyses of
myeloid cell line using humanTNFcDNA probes (3). As expected, LT-I did not
hybridize to any band (Fig . 1 A, lanes 5 and 6). Similar results were obtained
FIGURE 1 .
￿
Hybridization ofTNFandLT probes to myeloid (ML-1) andT(HSB-2) leukemic
cell lines . Poly(A)*-RNA was isolated from control (C lanes) or PMA-treated (4 h, 30 ng/ml;
P lanes) ML-1 (A) or HSB-2 (B) cell lines as described in Materialsand Methods . A total of 5
,ug of ML-1 and 10 wg of HSB-2Poly(A)+-RNA wasloaded in each lane . Northern blot analysis
was performed as in Materials and Methods. Mouse TNF plasmid DNA was labeled by nick
translation to a specific activity of 1-4 X 108 cpm/,ug, heat denatured, andadded to the blots
at 0.5-1 X 106 cpm/ml . Oligonucleotide probes TNF-I and LT-1 were labeled by kinasing to
a specific activity of 4-8 X 10 8 cpm/,ugand used at 0.5-1 X 106 cpm/ml . End-labeled Hind
III cut phage X DNA were heat denatured and used as molecular weight markers. The sizes
of the hybridized bands are calculated molecular weights for RNA. The blotswere hybridized
with mouse TNF (lanes 1 and 2), TNF-I (lanes 3 and 4), LT-I (lanes 5 and 6), TNF-I plus
LT-1 (lanes 7 and 8), and#actin (lanes 9 and 10) .SUNG ET AL .
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with two other myelomonocytic leukemia cell lines, KG-1 and U-937 . In the case
of the leukemic T cell line HSB-2, the same 1 .7-kb and 2.9-kb bands hybridized
to the mouse TNF cDNA and TNF-I probes in both control and PMA-treated
cells . However, LT-I hybridized to a 1 .4-kb mRNA . This 1 .4-kb mRNA band
was identified in all seven leukemicT cell lines as discussed later and three EBV-
transformed B lymphoblastoid lines . The molecular weight of this mRNA is
identical to that ofhuman LT mRNA . The differences in TNF and LT expres-
sions between ML-1 and HSB-2 were most evident when the Northern blots
were probed with a mixture of TNF and LT oligonucleotides (Fig . 1, lanes 7
and 8) . Although not shown, similar results were obtained when TNF-11 and
LT-11 were used. Northern blots results obtained with the oligonucleotide and
mouse TNF probes have also been confirmed by the use of a human genomic
TNF Pst I fragment . As with all Northern blot analyses presented in this study,
the blots were probed with ,B actin cDNA . In Fig . 1, ,B actin probing shows that
similar amounts ofmRNA were loaded in each lane for electrophoresis . From
the above analyses, the specificities ofTNF and LT oligonucleotide probes were
established .
Expression of TNF and LT mRNA in T Cell Lines.
￿
Seven T cell lines were
studied for their responses to PMA stimulation to make TNF and LT mRNA .
In dose-response studies with CEM cells, it was determined that 10-30 ng/ml
was the optimal dose range without toxicity to the cells . For subsequent experi-
ments, 30 ng/ml ofPMA was used . As shown in Fig . 2, all control cell cultures
accumulated low-to-undetectable levels of TNF mRNA except HSB-2, which
accumulated high TNF mRNA levels . With PMA treatment, TNF mRNA was
detected in all seven cell lines . The accumulations were severalfold over that in
unstimulated cells . CEM, HSB-2, and SKW-3 cells expressed the highest level of
TNF mRNA, while Jurkat and Molt-4 cells expressed it at barely detectable
levels . When the same blots were probed by LT-I, the 1 .4-kb LT mRNA was
detected in all cell lines without stimulation, and this mRNA was markedly
increased upon PMA stimulation (Fig . 2B) . Thus, there were considerable
differences among T cell lines in their expressions of TNF and LT mRNAs .
Qualitatively, the accumulations ofTNF and LT mRNAs were similar in CEM,
HSB-2, and MT-1 cells whereas more LTmRNA accumulation was detected in
Jurkat, KE-4, Molt-4,andSKW-3 cells . In addition to cell surface marker analysis,
these cell lines were shown to be of T cell origin by using cell type-specific
probes . These cell lines either expressed the correct-sized rearranged T,BmRNA
as shown in Fig . 2C or expressed CD2 mRNA (data not shown) . None of these
lines mademRNA that hybridized with the myeloid-specific chronic granuloma-
tous disease 30mer oligonucleotide probe (27) .
Potentiation ofPMA-induced TNF and LT mRNA Accumulation by A23187 and
Anti-CD3 mAb . The effects of PMA and calcium ionophore A23187 on the
induction of TNF and LT mRNA accumulations were investigated in detail in
selected T cell lines . As shown in Fig . 3, lane 1, small but detectable amounts of
TNF and LT mRNAs were made by the cell line CEM without the addition of
either PMA or A23187 . A23187 by itself in doses between 0.3 and 3 JM had
minimal effects on TNF or LT mRNA accumulation . Doses >10 jM were toxic
to the cells . At 30 ng/ml ofPMA, an increase in TNF mRNA level was detected942 ANTI-CD3 ANTIBODY AND TUMOR NECROSIS FACTOR PRODUCTION
FIGURE 2.
￿
TNFand LT mRNA expression in humanT cell lines . Poly(A)'-RNA (10 ag per
lane) from the humanT cell lines CEM (lanes 1 and 2), Jurkat (lanes3and 4), KE-4 (lanes 5
and 6), Molt-4 (lanes 7 and 8), HSB-2 (lanes 9 and 10), MT-1 (lanes 11 and 12), and SKW-3
(lanes 13 and 14) were fractionated and hybridized to TNF-I (A), LT-I (B), human T cell
receptor TO chain (C), and chicken # actin (D) probes as in Fig . 1. TNF-I and LT-I
oligonucleotide probes were labeled to thesame specificity andused in the same concentration
to hybridize to duplicate blots, respectively . After exposure to XK-1 films, the blots were
washed for 20 min at 100°C in 0.1x SSC and I% SDS to remove the probes and reused to
hybridize with the TO and actin probes. The exposure time for TNF- and LT-probed blots
was 36 h . The molecular weight on the left were from Hind III cut DNA markers and the
size markers on the left designated calculated RNA sizes . RNA from control cells (C lanes)
and PMA-treated cells (4 h, 30 ng/ml ; P lanes) were analyzed for each cell line .SUNG ET AL .
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FIGURE 3 .
￿
Stimulation of the expression of TNF and LT mRNA in CEM by PMA and
A23187. CEM cells were stimulated with 1 pM A23187 (lanes 2-5), 30 ng/ml PMA (lanes 6-
9),30 ng/ml PMA plus0.1 pM A23187 (lanes 10-13), and30 ng/mlPMAplus I 'UM A23187
(lanes 15-19) at 2 x 106 cells/ml in RPMI-1640 with 10% FCS for 1-8 h, chilled on ice, and
harvested for RNA extraction . Northern blot hybridization to TNF-I (A), LT-I (B), and ,8
actin (C) probes were performed as in Fig . 1 . A total of 20 fag of total RNA was loaded in
each lane . Identical blots were probed with TNF-I or LT-I, exposed to XK-1 films, and
stripped of the probes by boiling . Thesame blotswere then rehybridized to the0 actinprobe.
The exposures for panelsA andB were 24 h .
1 h after incubation (Fig . 3, lane 6) . The maximal TNF mRNA accumulation
was reached by 4 h of incubation (Fig. 3, lane 8) . Similar kinetics were seen
regarding LT mRNA . A23187 at 1-3 jM in combination with 3-100 ng/ml
PMA at 4 h stimulated both TNF and LTmRNA expression three- to fourfold
above the level achieved by PMA stimulation alone (not shown) . With an
increased dosage (1 uM) of A23187 in combination with 30 ng/ml PMA, the
peak of TNF mRNA accumulation was shifted to 1-2 h after the addition of
these agents (Fig. 3) . In contrast, the peak of LTmRNA accumulation remained
at 4 h . Thus, for the stimulation of cellularTNF and LT mRNA accumulations,
there was synergy between PMA and A23187 . Similar results were obtained in
the case ofSKW-3 .
mAb T3-II (IgGI anti-CD3) at 1 Ag/ml was examined for its ability to
potentiate PMA in stimulatingTNF andLTmRNA accumulations in CEM cells .944 ANTI-CD3 ANTIBODY AND TUMOR NECROSIS FACTOR PRODUCTION
FIGURE 4 .
￿
Effects ofPMA and anti-CD3 on TNF and LT mRNA accumulation by CEM
cells. Cells at 2 X I0 6/ml were treated with I fag/ml anti-CD3 (T3-II) (lanes 1-5), 30 ng/ml
PMA (lanes 6-10), or the combination of the two reagents (lanes 11-15) for the indicated
period of time . 20 kg of total RNA were loaded in each lane and Northern blot hybridizations
to TNF-I (A), LT-I (B), and ,B actin (D) were performed as in Figs. I and 4. Conditions of
hybridization and washing of blots probed with IL-2-R (C) were identical to that used for ,B
actin hybridization . The exposure time of blots to the filmswere 24 h for A, 57 h for B, and
5 d for C.
mAb T3-II was chosen because it induced significant increases in intracellular
free [Ca"] (data not shown) . As shown in Fig . 4, mAb T3-II had no discernible
effect on TNF and LT mRNA levels in CEM cells. In conjunction with PMA,
T3-II induced more TNFmRNA accumulation . This combination also sustained
TNF mRNA accumulation for a longer period of time . However, the peak of
TNF mRNA accumulation remained at 4 h . For comparison, the cDNA of IL-
2-R was used to probe the same blot . As shown in Fig. 4C, PMA inducedCEM
cells to make IL-2-R mRNA . T3-II was synergistic with PMA to cause increasedSUNG ET AL .
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and more prolonged accumulation of IL-2-R mRNA . mRNA for IL-2-R peaked
at 14 h . mAb T3-1I was not synergistic with PMA in inducing TNF mRNA
accumulation in the CD3- cell line SKW-3 (not shown) . The accumulation of IL-
2 mRNA could be readily detected in SKW-3 stimulated with 30 ng/ml PMA
and 1 ,uM A23187 . This expression peaked at 2-4 h after stimulation (not
shown) .
Ofthe sevenT cell lines studied, Jurkat and Molt-4 cells synthesized little TNF
mRNA when PMA was added . Although both cell lines were positive for CD3,
they showed little response to mAb T3-II in the presence of PMA . In the
presence of 1 uM A23187, a synergistic response toPMA was detected in Molt-
4 but not in Jurkat cells, resulting in an approximately fivefold increase in TNF
mRNA accumulation (not shown) .
Induction ofTNF and LT mRNAs by PMA and mAb T3-II in Peripheral Blood T
Cells. Highly purified peripheral blood T cells, which contained <0.01% mono-
cytes and <1% B cells, were used to demonstrate the induction ofTNF and LT
mRNA syntheses by PMA and mAb T3-Il . These T cell populations did not
proliferate in the presence of mAb T3-11 alone, indicating the absence of
monocytes . As shown in Fig . 5A, PMA stimulated the increase in TNF mRNA
accumulation at both 4 and 18 h while mAb T3-II did not have detectable
effects . However, mAb T3-II increased PMA-induced TNF and LT mRNA
accumulation by 5-10-fold . The maximal response for TNF mRNA accumula-
tion occurred at ^-4 h (Fig . 5B), in contrast to the LT mRNA accumulation
which peaked between 8 and 18 h . IL-2 mRNA accumulation in these T cells
peaked between 4 and 8 h when stimulated withPMA plus anti-CD3 (not shown) .
The amounts of fl actin mRNA increased with time when cells were treated with
PMA and mAb T3-1I . This was due to an increase in mRNA synthesis upon
activation . It is of note, however, that TNF and LT mRNA syntheses peaked
before total mRNA accumulation per cell reached its highest level at 18 h .
The increase in TNF mRNA at 4-18 h in response to PMA and mAb T3-11
was not due to contaminating monocytes because of the purity of the T cell
preparations used in these experiments . As an added control, studies of isolated
monocytes were carried out . Monocyte populations isolated according to Wright
and Silverstein (33) were shown to reach peak TNFmRNA accumulation within
1 h after the addition of either PMA or IFN-y plus LPS . In addition, PMA at
doses >10 ng/ml was toxic to freshly isolated monocytes . With 10 ng/ml of
PMA, 40% of the monocytes were stained by trypan blue after 4 h of incubation
and little TNF mRNA was detected . By 18 h, all monocytes were trypan blue
positive . Neither TNFmRNA nor0 actinmRNA could be detectedby Northern
blot analysis . Anexperiment in which monocytes were added to the T lymphocyte
cultures was further carried out. The addition of increasing numbers of mono-
cytes (0.1-1% of total cell number) had no appreciable effect on TNF mRNA
accumulation at 18 h in peripheral blood T cell populations stimulated by PMA
and mAb T3-II (not shown) .
Secretion of TNF by Activated CEM Leukemic T Cells and Peripheral Blood T
Cells . The secretion ofTNF by CEM cellswas analyzed by Western blot analysis
and by assaying cytotoxicity to L cells . mAb C16 was used for Western blot
analysis. It reacted with isolated 17-kD TNF as well as rTNF but did not bind946 ANTI-CD3 ANTIBODY AND TUMOR NECROSIS FACTOR PRODUCTION
FIGURE 5 .
￿
Expression ofTNF and LT mRNA in peripheral blood T cells stimulated with
PMA and anti-CD3 . (A) Extensively purified T cells at 106 cells/ml in medium (50 x 10 6 per
sample) were treated with control medium (lanes 1 and 5), 1 fag/ml T3-II anti-CD3 antibody
(lanes 2 and 6), 10 ng/ml PMA (lanes 3 and 7), or the combination of PMA and anti-CD3
(lanes 4 and8) for 4 (lanes 1-4) or 18 h (lanes 5-8) . The total RNA extracted as described in
Fig . 1 was quantitated by using an aliquot(5% of the sample) for absorbance measurement at
260 nm and then split into two halves and loaded into two gels . Northern blot hybridization
to TNF-I and LT-I were performed as in Fig . 1 . (B)The time course ofTNFand LTmRNA
accumulation by purifiedT cells stimulated with 10 ng/ml PMA plus 1 wg/ml T3-II anti-CD3
antibody. The procedurewas thesame asA. Samples in lanes 1-4 were from one experiment
and samples in lanes 5 and 6 were from a different experiment due to the limitation of cell
numbers .
isolated LT . CEM cells were grown in serum-free medium for 24 h with various
stimuli. As shown in Fig . 6, unstimulated CEM cells secreted little stainableTNF
(Fig . 6, lane 2) . The addition of A23187 enhanced TNF secretion (Fig . 6, lane
4) . However, a more marked increase in TNF was detected when PMA was
added (Fig. 6, lane 6) . With the combination of PMA and A23187, maximal
TNF secretion was detected (Fig. 6, lane 8) . Similar results were obtained in two
additional experiments .
Actinomycin D-treated L-929 cells were used as targets for cytotoxicity assays .
To distinguish between TNF and LT activities, mAb E43 was chosen because it
blocked TNF activity in the L cell assay and it had no effect on LT activities . In
a typical experiment, the supernatant of CEM treated with 30 ng/ml PMA and
0.1 uM A23187 was shown to have 17.6 U/ml cytotoxic activity while the
unstimulated supernatant had no cytotoxic activity . In the presence of 1 Ag/ml
of mAb E43, the cytotoxic activity was reduced to 1 .7 U/ml . The serum-free
supernatant of stimulated CEM cells was passed through a Con A column to
absorb LT activity . The flow-through remained active at 14.4 U/ml . Similar
results were obtained with two additional experiments.SUNG ET AL .
FIGURE 6. TNF production by T cell line stimulated with PMA and A23187 . CEM cells
were washed twice with PBS and resuspended in RPMI-1640 with 10 mM Hepes, pH 7 .4, at
2.5 X 108/ml . 50-ml samples were treated with no addition (lanes 1 and 2), 0.1 UM A23187
(lanes 3 and 4), 30 ng/ml PMA (lanes Sand6) or 0.1 uM A23187 plus 30 ng/ml PMA (lanes
7and 8) for 24 h . Thesupernatants were concentrated to 300 ul,made 1% in octyl glucoside,
and 50-Wl samples were subjected to electrophoresis in 12.5% SDS polyacrylamide gels under
reducingconditions. Transfer ofproteins to nylon membranes (30)and blocking ofnonspecific
binding by nonfat dry milk (31) have been described . The lanes were cut into 3-mm strips and
reacted with 1 :5 dilution of control hybridoma supernatant (HDP-1, IgGI anti-DNP Ab ; lanes
1, 3, S, and 7) or anti-TNF hybridoma supernatant (C16, IgGI anti-TNF antibody ; lanes 2, 4,
6, and 8) for 4 h, washed, andreacted with 10 rig/ml "'I-labeled affinity-purified goat anti-
mouse IgG antibody (sp act ~ 4 X 108 cpm/lig). After washing, the blots were mounted and
exposed to Cronex 4 films on lightning plus intensifying screens . Positions of Rainbow
prestained molecular weight markersareshown on the left .
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FIGURE 7 .
￿
TNF production by peripheral blood T
cells stimulated with anti-CD3 plus PMA. Purified
peripheral bloodTcells were treated with PMAat 10
ng/mlandanti-CD3 (T3-II) at 2 ,kg/ml and incubated
for8h (lanes 1 and 2) or 18 h (lanes3and 4) . Western
blot analysis was performed as in Fig . 8, except that
proteins were transferred to nitrocellulose mem-
branes . Lanes 1 and 3 were reacted with control
primary antibody (HDP-1) and lanes 2 and 4 were
reacted with anti-TNF antibody (C16). The positions
of the Rainbow molecular mass markers (x 10-') and
the position of the 17-kD TNFmonomer is shown on
the left . Thearrows on the right indicate the position
of theH and L chains of the anti-CD3 mouse mAb
used in theT cell stimulation . The Ig chains reacted
strongly with the iodinated secondary goat anti-
mouse antibody .
Experiments were carried out with peripheral blood T cells stimulated with
PMA at 10 ng/ml and mAb T3-11 at 2 ttg/ml . With 18 h of incubation, Western
blot analysis revealed a 17-kD band by mAb C16 (Fig . 7) . At 8 h, this band was
not detected. In cytotoxicity assays, the supernatant from day I culture revealed
60.2 U/ml . In the presence of anti-TNF mAb E43, 5 .0 U/ml remained . There
was 74.4 U/ml cytotoxic activity in day 2 supernatant and 22.5 U/ml was detected
in the presence of mAb E43 . In day 3 supernatant, 78 .0 U/ml cytotoxic activity
was detected . 34 U/ml remained in the presence ofmAb E43 . Without stimuli,
no cytotoxic activity was detected . Similar data were obtained in one additional
experiment .
Discussion
The expression ofTNF and LT mRNAs by leukemic cell lines was studied by
Northern blot analysis . The specificities of the oligonucleotide probes were
documented extensively . Both TNF and LT oligonucleotide probes identified
mRNA species of expected sizes ; i.e., 1 .7 kb and 1 .4 kb, respectively . The results
obtained with the TNF oligonucleotide probes were similar to those obtained
with a murine cDNA probe and finally confirmed with a human genomic TNF
Pst I segment . In myeloid cell lines ML-1, KG-1, and U-937, only the 1 .7-kb
TNF mRNA was identified . There were no LT mRNA detected in these three
lines . The lack of homologous sequences in known genes registered with Gen-
Bank further supports the specificity of the probes .
Results from the TNF probes showed that all T cell lines studied synthesized
TNFmRNA . All lines except HSB-2 expressed little TNFmRNA when unstim-
ulated, but could be induced to accumulate varying levels of TNF mRNA . The
degree of accumulation of TNF mRNA by PMA stimulation did not correlate
with presence of the CD4 or CD8 surface markers . This result is consistent withSUNG ET AL .
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peripheral bloodT cell studies which showed that both CD4+ and CD8+T cells
synthesize comparable levels of TNF (12) . Though Molt-4 and Jurkat cells
accumulated little TNF mRNA during PMA stimulation, one of the lines, Molt-
4, could be further stimulated by A23187 to express a higher level of TNF
mRNA . This response of Molt-4 cells to the two signals is similar to that of a
Jurkat cell line studied by Weiss et al . in IL-2 mRNA synthesis (13) . The low
TNF mRNA levels in PMA-stimulated Jurkat and Molt-4 cells probably led
Goeddel et al . (3) to conclude that T lymphocyte cell lines do not synthesize
TNFmRNA . HSB-2 behaved anomalously in that it accumulated high levels of
TNFmRNA without stimulation . Thebases of this constitutiveMRNA synthesis
and of the varying level ofmRNA accumulation in different T cell lines after
PMA stimulation are of interest. There may be a heterogeneity in the humanT
cell population, in that subpopulations ofT cells may synthesize LT andTNF at
different rates in response to the same stimuli. This difference in responsiveness
may be directly related to their immune functions . Our results concerning the
T cell leukemic cell lines and those regarding monocytes offer further evidence
that TNF and LT are expressed independently . This is remarkable because the
two genes have been localized to be 1 .2 kb apart on chromosome 6 and were
shown to share considerable homology (3, 5) .
Similar approaches were used to show that peripheral blood T cells could be
induced to make TNF. The T cell preparations were extensively depleted of
monocytes, as demonstrated by cell marker analysis and nonspecific esterase
staining . Functionally, these T cell preparations did not proliferate in response
to IgGI or IgG2a anti-CD3 mAb or PHA. With these T cell populations, anti-
CD3 mAb was shown to markedly augment PMA in the induction of TNF
mRNA synthesis and accumulation . This responsiveness to anti-CD3 mAbs is a
unique property ofT cells. Thus, this observation provides further evidence that
the cell population responsible for theTNFsynthesis measured in our experiment
is indeed of theT cell lineage. Other supportive evidence includes experiments
in which the addition ofmonocytes to theT cell populations did not substantially
alter the experimental results. This can in part be accounted for by our demon-
stration that monocytes do not survive the prolonged exposure to the level of
PMA used inour experiment . Thus, ourresults indicate that both freshly isolated
T cells and leukemic T cell lines are inducible to make TNF. TNF and LT
mRNA expression in peripheral blood T cells is different from that in T cell
lines in several features . Resting peripheral bloodT lymphocytes do not synthe-
size TNF or LT mRNA (Fig . 5) . Though PMA stimulates TNF and LT mRNA
expression, anti-CD3 further increases the accumulation ofTNF andLTmRNA
5-10-fold in peripheral blood T cells, in contrast to the small increase caused by
anti-CD3 in the PMA-stimulated cell line,CEM . The maximum accumulation of
LT mRNA in peripheral blood T cells occurs at 8-18 h, in comparison to that
in cell lines which occurs at 4 h. These results extend and add support to the
recent observation by Cuturi et al . (12) .
The time course of TNF, LT, and IL-2 mRNA accumulations in peripheral
blood T lymphocytes stimulated by PMA plus anti-CD3 are different . TNF and
LTmRNA accumulations occurred maximally at 4 h and 8-18 h after stimula-
tion, respectively . The maximal IL-2 mRNA accumulation in these stimulated950 ANTI-CD3 ANTIBODY AND TUMOR NECROSIS FACTOR PRODUCTION
cells occurred at 4-8 h, intermediate between the peak times of TNF and LT
mRNA accumulations. Studies by Granelli-Piperno et al. (34) on IFN--y and IL-
2 mRNA accumulations in PHA- and PMA-stimulated T cells showed that the
accumulations of both mRNAs occurred maximally at -12 h after stimulation in
unprimed peripheral blood T cells. These studies and ours show that maximal
accumulation in stimulated unprimed T cells occurs the earliest for TNF mRNA,
followed by IL-2, IFN-,y, and LT mRNAs.
Although the stimulation of TNF and LT mRNA accumulations in T cell lines
and peripheral blood T cells by PMA, anti-CD3, or A23187, alone or in
combination, were examined in this study, the effects of each of the stimulants
on TNF and LT gene transcription, mRNA degradation, and rate of translation
have not been elucidated. TNF and LT mRNAs contain a canonical AUUA
sequence that occurs in a number of growth factor mRNAs and is believed to be
responsible for the rapid degradation of these messages (35). The results that
cycloheximide elevates TNF mRNA level support the notion that such degra-
dation occurs (3). TNF and LT syntheses may also be under the translational
control which occurs in the synthesis of mouse TNF (36). The relative proportion
of LT and TNF produced in a T cell hybridoma also varies with the agent used
to stimulate the T cells (12). The separate effects of different T cell-activating
agents on each of these processes will need to be studied in order to more fully
understand the control mechanisms of TNF and LT syntheses in T cells.
Although monocytes have been thought to be the major source of TNF, these
studies and others (6-12) establish that T cells, NK cells, as well as certain
nonhematopoietic cells, are capable of producing TNF. Preliminary data in our
laboratory indicate that B cells under appropriate stimuli do make TNF. It is
likely that TNF is produced by even a wider range oftissues and cells. In addition
to the established diverse effects of TNF, newer biological functions will un-
doubtedly be discovered. In particular relevance to this paper, it would be of
considerable interest to determine whether lymphocytic infiltrates in chronic
inflammatory lesions are a major source of TNF. This is particularly germane in
view of the finding by Dayer et al. (37) that TNF is a potent stimulant of synovial
cells and dermal fibroblasts for the production of collagenase and prostaglandin
E2.
Summary
The induction of mRNA synthesis and accumulation of TNF/cachectin and
lymphotoxin (LT) mRNAs in T leukemic cell lines and freshly isolated T cells
were studied by Northern blot analyses. Without stimulation, TNF mRNA was
barely detected in four T cell lines (CEM, KE4, MT-1, and SKW-3) and not
detectable in Molt-4 and Jurkat cells, while a considerable amount of TNF
mRNA was observed in HSB-2 cells. When stimulated by PMA, these T cell lines
accumulated varying levels of TNF mRNA. All seven T cell lines expressed LT
mRNA when unstimulated and responded well to PMA by increased accumula-
tion of LT mRNA. The calcium ionophore A23187 by itself had no effect on
TNF and LT mRNA accumulations in these cell lines. The CD3' T cell lines
did not respond to anti-CD3 mAb T3-II alone. However, A23187 and mAb T3-
II further elevated TNF and LT mRNA accumulations in PMA-treated T cellSUNG ET AL.
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lines . Synergism between PMA and mAb T3-II was modest in the CD3+ cell
lines . A slight difference in kinetics of TNF and LT mRNA accumulations was
noted . In addition, heterogeneities in TNF and LT expressions by these cell
lines in responses to PMA and other stimuli were observed . In monocyte-depleted
peripheral blood T cell populations, PMA was able to induce both TNF and LT
mRNA syntheses . This effect was potentiated markedly by the addition of anti-
CD3 mAb T3-11 . This synergistic response to anti-CD3 mAb and PMA provided
further evidence thatT cells were the source ofTNF synthesis in these cultures .
There was a difference in the kinetics ofTNF mRNA accumulation and that of
LT mRNA . Maximal accumulation of TNF mRNA occurred at 4 h while 8-18
h was required for maximal LTmRNA accumulation . IL-2mRNA accumulated
at an intermediate peak time of 4-8 h . Western blot analyses and cytotoxicity
assays with L cells as targets indicated that these T cell linesand peripheral blood
T cells secreted TNF . These results provide further evidence thathumanT cells
are capable ofmaking TNF as well as LT under appropriate stimulations . Their
productions are an integral part of T cell response to activation signals . In
addition, it appears that the production of these two closely related molecules is
independently regulated .
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